ADDED
apyx20251231_10k.htm 0000719135 Apyx Medical Corp false --12-31 FY 2025 true The outsourced Chief Information Security Officer ( CISO ) works closely with the Chief Financial Officer to collectively manage our global information security, information technology and data privacy programs.
true true false 1,020 1,000 1,207 1,032 0.001 0.001 10,000,000 10,000,000 0 0 0 0 0.001 0.001 75,000,000 75,000,000 41,785,946 41,785,946 37,793,886 37,793,886 http://fasb.org/us-gaap/2025#OtherOperatingIncomeExpenseNet 8 5 1.0 4 2 1 5 http://fasb.org/us-gaap/2025#SecuredOvernightFinancingRateSofrMember 0 2022 2023 2024 2021 2022 2023 2024 3 3 0.3 0.70 1.47 0.80 1.87 2 false false false false true false The states that contribute to the majority (greater than 50%) of the tax effect in this category includes Florida and California for each of the years ended December 31, 2025 and 2024.
For the Advanced Energy segment, all other expenses includes salaries and related costs, research and development, professional services, including marketing and physician consulting, and other selling, general, and administrative expenses such as travel and entertainment, advertising, trade show fees and meeting and training costs.
As of March 9, 2026, 41,829,226 shares of the registrant s $0.001 par value common stock were outstanding.
We are a surgical aesthetics company with a passion for elevating people s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion and the AYON Body Contouring System TM ( AYON ) in the cosmetic surgery market and J-Plasma in the hospital surgical market.
AYON is an FDA-cleared, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform.
It seamlessly integrates fat removal, closed loop contouring, and Renuvion s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver comprehensive body contouring treatments for patients.
We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.
Recent Business Developments On May 13, 2025, we announced that we had received 510(k) clearance from the U.S.
We completed the soft launch of AYON, leveraging our relationships with key surgeons in critical geographies.
REMOVED
As of March 11, 2025, 37,793,886 shares of the registrant s $0.001 par value common stock were outstanding.
We are an advanced energy technology company with a passion for elevating people s lives through innovative products, including our Helium Plasma Platform Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market.
We also leverage our deep expertise and decades of experience in unique waveforms through Original Equipment Manufacturer ( OEM ) agreements with other medical device manufacturers.
Recent Business Developments On January 6, 2025, we announced that we had submitted a 510(k) premarket notification to the FDA for the AYON Body Contouring System ("AYON").
The initial submission for AYON includes the following: Infiltration Dual aspiration to facilitate simultaneous users Ultrasound-assisted liposuction Electrocoagulation to support procedures requiring removal of excess tissue Volume enhancement capabilities Renuvion treatment to address loose and lax skin During 2025, we plan to expand the indications with an additional 510(k) submission for AYON to include power assisted liposuction.
For the year ended December 31, 2024, we incurred a loss from operations of $18.8 million and used $18.0 million of cash in operations.
As of December 31, 2024, we had cash and cash equivalents of $31.7 million.
We estimate the annualized future cost savings from the reduction in force to be approximately $4.3 million, which we expect to contribute to our goal of decreasing losses and achieving cash-flow breakeven.
In addition to the organizational changes, we have identified other direct cost savings we anticipate achieving in 2025.
The identified cost savings include reductions in professional fees, lower research and development costs as we complete the development of AYON, lower credit card fees and stock-based compensation.